Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency. Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients. Hence, the providers are more likely to adopt biosimilars as a “reference […]Read More
The concept of telemedicine has evolved in recent years. As people are demanding easier ways to avail of medical treatment and diagnosis, there have been several advances in telemedicine. Telemedicine is a method that involves providing clinical services through a distance. Through telemedicine, the user doesn’t necessarily have to be present at the hospital or […]Read More
On September 2, 2020, Octavus Consulting and DealForma will present their most recent data and trends on dealmaking across biopharma, device, diagnostics, and digital health. Healthcare and life sciences deal and venture activity through August 2020 has not slowed down despite the challenges thrown at business leaders globally. We will review recent trends covering the […]Read More
Shots: Cadalimab will be available in 40mg/0.8ml as a pre-filled syringe and is targeted for the reduction in signs and symptoms of Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, and Psoriasis Additionally, Cadila has launched 3 more biosimilar products Bevaro, Ritucad, and NuPTH in the last 2 months Adalimumab is a mAb and […]Read More
The US FDA has approved multiple NDAs and BLAs in July 2020, leading to treatments for patients and advances in the health care industry. The Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) have approved 59 novel products so far in 2020, including 8 in July 2020. Additionally, […]Read More
K. K. Consulting Services has conducted this survey by contacting around 2200 medical representatives across the India using google forms. Objective of Survey The purpose of this survey is to design a platform for pharmaceutical sales professionals (PSP) to share their opinion about business continuity challenges faced by them due to the present COVID pandemic […]Read More
Shots: BIOEQ will sponsor the P-III study which will assess the FYB203 vs Eylea in patients with neovascular age-related macular degeneration (nAMD) to evaluate its efficacy, safety and immunogenicity. Additionally, the design of the study is developed in collaboration with the USFDA, EMA, PMDA The second program in ophthalmology will aim to strengthen and expand […]Read More
Shots: The EMA’s CHMP positive opinion was provided in June and is the fifth product which received the EU approval for autoimmune diseases and tumor diseases The P-III study results of Abincio which involves 763 patients non-small cell lung cancer (NSCLC) patients and demonstrated the risk ratio of ORR vs original product, also presented at […]Read More
Shots: The two companies will work together to research, discover, and develop therapeutic options related to the deficiency of the protein GBA which is a gene linked to Gaucher disease The collaboration will combine Evotec’s iPSC platform and drug discovery and development capabilities with Centogene’s global rare disease platform, including iPSC lines The collaboration follows […]Read More
Shots: The companies will use BioSymetrics Contingent-AI engine to characterize high-risk populations, measure and predict disease progression based on biological risk factors and treatment course and identify markers for clinical phenotype and severity of the disease The focus of the collaboration to predict the onset and severity of COVID-19 among different populations using machine learning […]Read More
Copyright ©2020 PharmaShots | Powered by Octavus Consulting
